A Single-centre Research Study to Evaluate the Care4Today® Heart Failure Platform.

NCT ID: NCT04371731

Last Updated: 2020-05-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

182 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-18

Study Completion Date

2018-04-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A research study to evaluate the impact of a novel care pathway for patients diagnosed with Heart Failure within Chiltern CCG, supported by an integrated clinical patient record. Assessment of patient outcomes following implementation of Care4Today(R) Heart Failure Platform.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an exploratory study to evaluate the impact of the novel Care4Today HF platform on a set of outcomes including hospital admission rate (primary diagnosis), 30 days post discharge readmission rate, length of hospital stay for patients with HF (primary and secondary diagnosis), patient quality of life, and patient clinical metrics. The study design includes comparison of two parallel cohorts: one where patients will be managed via the Care4Today HF platform (active cohort) and a second, where patients will be managed as per existing standards of care (control cohort).

Evaluation phase:

The evaluation phase will be set up to assess the potential benefits of the Care4Today HF platform. This will be implemented across 10 GP practices who will be part of the active cohort, within the Chiltern CCG region. The outcomes for these patients will be compared with the outcomes of patients in the control cohort over a one year period.

Patients pathway (for the active cohort):

Once the diagnosis of HF is confirmed, a HF specialist project nurse will register the patient on the Care4Today platform and provide the patient with instructions on how to use the patient portal, where patients can input various clinical measures, communicate with HCPs and track their condition. Complex patients, and/or patients that are deteriorating are referred to the community HF specialist nurse team where they will be monitored and managed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure With Reduced Ejection Fraction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Two arms, one using the platform to help manage their heart failure and one standard of care.
Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Arm

Active cohort will use the Care4today platform to help manage their heart failure

Group Type EXPERIMENTAL

Care4todayheart failure platform

Intervention Type OTHER

Platform allowing patients to enter information about their health at home, namely weight and BP and medications

Control arm

Control arm will contain standard of care heart failure treatment

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Care4todayheart failure platform

Platform allowing patients to enter information about their health at home, namely weight and BP and medications

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults 18 years of age or older with the primary diagnosis of heart failure
* Must have moderate to severe LVSD (ejection fraction \<= 40%) confirmed by an echocardiogram and/or other cardiac imaging

Exclusion Criteria

* Patients with right heart failure as a consequence of respiratory disease
* Patients with Heart Failure with preserved Ejection Fraction
* Patients with significant learning disability, or severe mental health conditions
* Patients with metabolic heart disease e.g. amyloid
* Patients with severe non-operable valve disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Janssen-Cilag Ltd.

INDUSTRY

Sponsor Role collaborator

Buckinghamshire Healthcare NHS Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RXQ682

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Enhancing Heart Failure Self-Care
NCT00526773 COMPLETED NA
Cardiac Cachexia in Advanced Heart Failure
NCT06259045 ACTIVE_NOT_RECRUITING
Ambulatory Heart Failure Service Model Study
NCT05556031 NOT_YET_RECRUITING